Small-Cap Momentum Watch: Upcoming Catalysts for November 2–6
11/2/20269 min read
From operational updates to conference participation, we've highlighted the small-cap events that could drive attention this week.
--
Companies with Material Events This Week
MNDR - Will launch its MaNaDr Health Operating Ecosystem in Singapore on November 2, 2026, followed by a phased global rollout over the following two months. The integrated platform combines MaNaDr's patient-facing virtual healthcare services with OtterSG's intelligent clinic management and electronic medical records system, enabling physicians to manage virtual and in-person consultations through a unified environment while improving patient data continuity and clinical workflows.
HOWL - Will present clinical and preclinical data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 4-8, 2026, in Phoenix, Arizona. An oral presentation on November 7 will highlight Phase 1/1b findings evaluating the tumor-activated IL-2 prodrug WTX-124 alone and in combination with pembrolizumab in patients with advanced solid tumors. Additional posters will cover the company's WTX-330 tumor-activated IL-12 program, including its Phase 1b/2 development in relapsed or refractory solid tumors.
CNTN - Expects trading of its tokenized common shares to begin as early as November 2, 2026, through an agreement with TSV LLC on the Canton Network. The company has engaged SEC-registered onchain transfer agent Fairmint to tokenize its shares as issuer-sponsored securities under the SEC's conditional Innovation Exemption framework. The planned trading platform is designed to support 24/7 availability, automated market-making, atomic settlement, and permissioned investor access, subject to applicable regulatory requirements.
RXRX - Will host a live business update on November 3, 2026, at 8:00 a.m. ET in conjunction with the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Annual Meeting in Denver. Management will review recent clinical developments, including REC-1245 monotherapy findings and REC-4481 data presented at the conference, followed by expert discussions on familial adenomatous polyposis (FAP). The event comes ahead of an anticipated regulatory update for REC-4881 by year-end 2026.
FMST - Expects to complete its transaction with Denison Mines on or about November 2, 2026, involving the sale of a 31% interest in the GR and Blackwing uranium properties, formation of two exploration joint ventures, and issuance of 1,031,191 five-year warrants exercisable at $1.80 per share. Total consideration is $650,000, with the transaction allowing Foremost to retain exposure to potential exploration discoveries while reducing its share of future exploration costs. Closing remains subject to regulatory and exchange approvals.
MIST - Will present clinical findings involving etripamil at two upcoming cardiovascular conferences. On November 2, 2026, at 12:00 p.m. PT, Chief Medical Officer Dr. David Bharucha will present an analysis of etripamil's efficacy, safety, and test-dose tolerability across multiple clinical trials in acute paroxysmal supraventricular tachycardia (PSVT) at TCT 2026 in San Diego. An additional presentation on November 7 at the American Heart Association Scientific Sessions in Chicago will examine recurrent PSVT following prior ablation using data from the RAPID study.
ANNX - Will host a virtual investor event on November 3, 2026, at 11:00 a.m. ET focused on its Phase 3 ARCHER II program in geographic atrophy, an advanced form of dry age-related macular degeneration. Management will review trial design, patient demographics, and communication plans for anticipated 15-month and 24-month clinical results beginning in Q4 2026. The event will also feature clinical investigator Dr. Roger Goldberg and an update on the company's ophthalmology team.
SGRX - Expects delivery of 16 NVIDIA Blackwell B300 servers, comprising 128 B300 GPUs, during the week of November 3, 2026, for its initial AI computing infrastructure deployment in Malaysia. Following delivery, inspection, rack installation, and testing are expected to require approximately one additional week, placing estimated commissioning activities around November 10-17, subject to actual delivery timing. Production deployment will follow successful testing and acceptance.
HOVR - Will participate in the Helicopter Association of Canada Annual Conference, November 3-5, 2026, in Victoria, British Columbia. Management will be available for discussions with aviation industry participants and prospective partners regarding its aerospace technologies, development initiatives, and potential commercial opportunities.
CATX - Will present cohort-level safety and efficacy results from Cohorts 1-3 of its lead radiopharmaceutical program, [212Pb]VMT-α-NET, at the NANETS 2026 Multidisciplinary Neuroendocrine Tumor Medical Symposium, November 5-7, in Las Vegas. The oral presentation is scheduled for November 5 during the 4:10-5:25 p.m. PST session and will highlight clinical findings in patients with advanced SSTR2-positive neuroendocrine tumors.
IFRX - Will host a virtual Capital Markets Event on November 3, 2026, from 8:00-9:00 a.m. ET focused on izicopan and its development strategy in ANCA-associated vasculitis (AAV). Management and medical experts will discuss the current treatment landscape, unmet medical needs, the drug's differentiated chemistry and metabolic properties, potential safety advantages, and the company's anticipated clinical development program.
RYDE - Will participate in Tencent Cloud's hackathon Demo Day on November 3, 2026, showcasing exploratory AI concepts for resolving ride-hailing disputes. The initiative focuses on prototype development and potential applications of artificial intelligence to customer service and dispute resolution, rather than a confirmed commercial product launch.
MAMO - Will showcase its Warrior 1500 UTV at the SEMA Show, November 3-6, 2026, in Las Vegas, Nevada. The event will provide opportunities to introduce the vehicle to automotive and powersports industry professionals, dealers, distributors, commercial fleet operators, government-related buyers, and prospective strategic partners.
KTTA - Will host a virtual key opinion leader event titled "Rethinking NF1 Treatment" on November 4, 2026, at 11:00 a.m. ET. Medical experts from the University of Alabama at Birmingham and Stanford University will discuss treatment challenges in neurofibromatosis type 1-associated cutaneous and plexiform neurofibromas. Management will also review PAS-004, its oral MEK inhibitor, Phase 1 solid tumor findings presented at ESMO 2026, and the potential clinical and commercial opportunity across NF1 indications.
GNPX - Will have research from its collaboration with Meharry Medical College featured at the Gerontological Society of America Annual Scientific Meeting, November 4-7, 2026, in National Harbor, Maryland. The research will examine the role of the TUSC2 tumor suppressor gene, used in the company's REQORSA gene therapy program, in mitochondrial biology, cellular resilience, and molecular processes associated with aging, potentially informing additional therapeutic applications beyond oncology.
MTVA - Will present Phase 1 clinical trial findings for DA-1726 at the Precision Liver Symposium on November 4, 2026, at 1:35 p.m. MT in Denver, Colorado. The oral presentation will highlight reductions in liver fat measured by MRI-PDFF and body weight, alongside relative preservation of lean mass, in a randomized placebo-controlled study of the company's dual GLP-1 and glucagon receptor agonist.
WVE - Will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET to present new data from its RNA medicines platform. The event will highlight advances in RNA interference, RNA editing, bifunctional modalities, and hepatic and extra-hepatic delivery technologies. Dr. Arun Sanyal will also discuss PNPLA3 I148M-associated liver disease and the potential of RNA editing to correct the underlying genetic variant.
INM - Will hold its annual general and special shareholder meeting on November 4, 2026, including a vote on the proposed return-of-capital distribution of contingent value rights (CVRs) associated with its planned merger with Mentari Therapeutics. November 5 has been established as the CVR distribution record date, conditional upon shareholder approval. Eligible shareholders of record would receive one CVR per common share, providing rights to potential future contingent payments under the merger agreement. Shares purchased on November 5 are not expected to qualify for the CVR distribution.
EVAX - Will present new immune-profiling data from its Phase 2 EVX-01 personalized cancer vaccine trial at the SITC Annual Meeting, November 4-8, 2026, in Phoenix. An oral presentation on November 6 and poster presentation on November 7 will examine neoantigen-specific T-cell responses and broader systemic immune modulation in patients with advanced melanoma receiving EVX-01 in combination with pembrolizumab. The findings build on previously reported clinical responses and provide additional insight into the vaccine's immune activity.
APVO - Will present research highlighting its CD40-directed multispecific immunotherapy platform at the SITC Annual Meeting, November 4-8, 2026, in Phoenix, Arizona. The presentation will focus on tumor-directed CD40 activation and the company's approach to engaging both innate and adaptive immune responses within the tumor microenvironment, supporting development of next-generation immunotherapies for solid tumors.
BCTX - Will present four preclinical research abstracts at the SITC Annual Meeting, November 4-8, 2026, in Phoenix. Presentations on November 6-7 will highlight the company's Bria-OTS+ personalized off-the-shelf cancer immunotherapy platform and BriaPro's BP-80 soluble CD80 program, tumor-targeted checkpoint inhibitors, and engineered CD80 variants designed to enhance antitumor immune responses.
IMRX - Will present preclinical findings at the SITC Annual Meeting on November 6, 2026, at 10:00 a.m. MT demonstrating that atebimetinib enhances PD-1 immune checkpoint blockade in RAS-mutant tumor models. The poster will examine the effects of intermittent MEK pathway inhibition and support the company's planned Phase 2 study evaluating atebimetinib in combination with PD-1 blockade in patients with lung cancer.
CLDI - Will present new preclinical findings at the SITC Annual Meeting, November 4-8, 2026, in Phoenix, Arizona. The presentations are expected to include GLP toxicology and IND-enabling study results developed following the company's June 2026 pre-IND meeting with the FDA, supporting continued advancement of its immunotherapy development program.
ALT - Will present new clinical and preclinical data for pemvidutide at the AASLD Liver Meeting 2026, November 5-9, in Denver, Colorado. Presentations on November 7-8 will highlight 48-week Phase 2b IMPACT findings in metabolic dysfunction-associated steatohepatitis (MASH), including reductions in liver stiffness, ELF score, liver fat, and liver enzymes, along with gastrointestinal tolerability results. Additional preclinical findings will examine pemvidutide's effects on alcohol consumption and potential applications in alcohol-associated liver disease.
IVA - Will present three research abstracts at the AASLD Liver Meeting 2026, November 5-9, in Denver, Colorado. The November 5 presentation will highlight epigenetic findings supporting the biological rationale for lanifibranor's balanced pan-PPAR mechanism, while two November 7 posters will examine antifibrotic activity across liver cell populations and improvements in liver sinusoidal endothelial dysfunction. Lanifibranor remains in the Phase 3 NATiV3 study for MASH, with topline results expected in Q4 2026.
GALT - Will present three analyses from its belapectin development program at the AASLD Liver Meeting 2026, November 5-9, in Denver, Colorado. A November 5 poster will examine noninvasive models of portal hypertension, followed by a November 7 Poster of Distinction and November 8 oral presentation evaluating risk prediction for variceal development in patients with MASH cirrhosis. The company also recently submitted its registrational Phase 3 belapectin trial protocol to the FDA.
GNS - Will host the Genius Future Summit on November 5-6, 2026, at Genius City in Nuanu, Bali. The two-day event will bring together entrepreneurs, business leaders, technology innovators, and industry professionals for discussions on emerging technologies, artificial intelligence, entrepreneurship, and long-term economic and business trends.
PLRX - Will present two preclinical and translational research posters involving PLN-101095 at the SITC Annual Meeting, November 4-8, in Phoenix, Arizona. The November 6 presentation will examine selective inhibition of integrins αvβ8 and αvβ1 to enhance immune checkpoint inhibitor responses, while the November 7 poster will highlight plasma biomarkers of immune activation associated with treatment sensitivity in patients with advanced solid tumors.
PRQR - Will deliver a plenary presentation at TIDES Europe 2026 on November 3 at 4:25 p.m. CET in Amsterdam, reviewing previously disclosed Phase 1 AX-0810 findings and AI-enabled advances in the discovery of next-generation RNA editing candidate AX-0811. The company will also present two AX-0810 posters at the AASLD Liver Meeting in Denver on November 5 and November 8, covering Phase 1 safety, pharmacokinetics, NTCP target engagement, and clinical proof-of-concept findings for its Axiomer RNA editing platform.
LGVN - Will present Phase 2b ELPIS II clinical trial data in a Late-Breaking Science podium presentation at the American Heart Association Scientific Sessions 2026, November 6-9, in Chicago. The presentation is scheduled for November 8 at 10:10 a.m. CT and will highlight efficacy and safety findings for laromestrocel as adjunctive therapy during Stage II palliation in patients with hypoplastic left heart syndrome.
RADX - Expects to receive the FDA's official End-of-Phase 2 meeting minutes for RAD101 around November 4, 2026, based on the company's October 5 guidance of approximately 30 days. The minutes will formalize the FDA's feedback on the proposed pivotal Phase 3 development program for RAD101, an investigational radiopharmaceutical imaging agent for brain metastases. The company is continuing Phase 3 readiness activities and plans to provide an additional regulatory and program update following receipt and review of the minutes.
LAB - Expects to complete the sale of its Microfluidics business to ARCHIMED around November 3-4, 2026, approximately 30 days after the October 4 definitive agreement and October 5 announcement.
--
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.
Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.